Key result
Cancer increases the overall risk of thrombosis sevenfold compared to noncancer patients, and low-molecular-weight heparins appear more effective than coumadin for treatment.
Population
Cancer patients at risk for or with thromboembolism
Design
Review
Authors
Loading...
Supports heightened thrombosis surveillance in cancer; leaves open optimal anticoagulant selection pending contemporary trials.
This review highlights the sevenfold increased risk of thrombosis in cancer patients and suggests low-molecular-weight heparins are more effective than coumadin for high-risk patients.
Adess et al. (2006) conducted a review in Thromboembolism in cancer patients. Cancer increases the overall risk of thrombosis sevenfold compared to noncancer patients, and low-molecular-weight heparins appear more effective than coumadin for treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: